Jpmorgan Chase & CO Kinnate Biopharma Inc. Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.24 - $2.66 $55,233 - $65,590	24,658 Added 39139.68%	24,721 $65,000
Q4 2023 Feb 12, 2024	SELL	$1.07 - $2.5 $9,427 - $22,027	-8,811 Reduced 99.29%	63 $0
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $10,126 - $24,288	7,338 Added 477.73%	8,874 $12,000
Q2 2023 Aug 11, 2023	SELL	$2.33 - $6.84 $52,061 - $152,832	-22,344 Reduced 93.57%	1,536 $4,000
Q1 2023 May 18, 2023	BUY	$3.46 - $7.98 $77,452 - $178,632	22,385 Added 1497.32%	23,880 $149,000
Q1 2023 May 11, 2023	SELL	$3.46 - $7.98 $56,823 - $131,055	-16,423 Reduced 91.66%	1,495 $9,000
Q4 2022 Feb 13, 2023	SELL	$5.26 - $12.19 $6,080 - $14,091	-1,156 Reduced 6.06%	17,918 $109,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $15,450 - $24,695	1,567 Added 8.95%	19,074 $228,000
Q2 2022 Aug 11, 2022	SELL	$7.43 - $13.0 $32,417 - $56,719	-4,363 Reduced 19.95%	17,507 $221,000
Q1 2022 May 11, 2022	BUY	$7.73 - $17.99 $29,033 - $67,570	3,756 Added 20.74%	21,870 $246,000
Q4 2021 Feb 10, 2022	BUY	$16.5 - $25.48 $77,484 - $119,654	4,696 Added 35.0%	18,114 $321,000
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $238,974 - $333,705	13,418 New	13,418 $309,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.